Business
: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
Reata’s Skyclarys is a treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system
Getty Images/iStockphoto
Referenced Symbols
The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.
Reata’s RETA stock jumped more than 180% in after-hours trading, after being halted in advance of the FDA’s decision.
The drug, omaveloxolone, is now…
